Investment
Features
FeesSafety
Academy
More
Pluang+

Health ETFs rise as LLY, UNH, and MRK report strong gains and drug approvals

Market News
17 Jul 2026
ETF Trends
View Source
Bullish
Health ETFs rise as LLY, UNH, and MRK report strong gains and drug approvals

Health stocks Eli Lilly (LLY), United Health Group (UNH), and Merck (MRK) have recently seen positive developments, including drug approvals and strong earnings. These gains have boosted their stock prices, with LLY up over 8% YTD, UNH up 25.8% YTD, and MRK up 19.9% YTD. Investors can gain diversified exposure to these companies through healthcare ETFs like VanEck Pharmaceutical ETF (PPH), Vanguard Health Care ETF (VHT), and State Street Health Care Select Sector SPDR ETF (XLV), which have all delivered solid returns around 21-27% over the past year. These ETFs offer a way to benefit from healthcare innovation and strong sector performance amid broader market shifts.

More News (LLY)

700,000 seniors start GLP-1 obesity treatments under Medicare, 70% choose Eli Lilly drugs

700,000 seniors start GLP-1 obesity treatments under Medicare, 70% choose Eli Lilly drugs

Since Medicare began covering obesity drugs in July, 700,000 new seniors have started GLP-1 treatments, with 70% using Eli Lilly's medicines. The coverage, part of a temporary "Bridge" program, allows eligible seniors to access weight loss drugs for ...

Market News
Bullish
19 hours ago
Eli Lilly's revenue soars 48% but stock lags; $1,500 share price possible by 2027 with key drug approvals.

Eli Lilly's revenue soars 48% but stock lags; $1,500 share price possible by 2027 with key drug approvals.

Eli Lilly reported a remarkable 48% revenue growth driven by strong sales of Mounjaro and Zepbound, yet its stock price remains nearly flat this year. Despite recent stock volatility due to price cuts, acquisition charges, and competition concerns, a...

Analyst Insights
Bullish
20 hours ago
Novo Nordisk shares drop 7% as new targets fail to ease weight-loss drug market concerns

Novo Nordisk shares drop 7% as new targets fail to ease weight-loss drug market concerns

Novo Nordisk's shares fell over 7% after the company announced long-term targets that failed to reassure investors about competition in the weight-loss drug market. The Danish drugmaker plans to launch multiple blockbuster drugs by 2030 and aims for ...

Market News
Bearish
21 hours ago
Nvidia's AI growth outpaces Eli Lilly's drug sales for next decade potential

Nvidia's AI growth outpaces Eli Lilly's drug sales for next decade potential

Nvidia and Eli Lilly both exceeded earnings expectations, but Nvidia's AI-driven data center growth offers a stronger long-term investment opportunity. Nvidia posted $96.22 billion in revenue, driven by AI infrastructure demand and supply constraints...

Market News
Bullish
23 hours ago
Novo Nordisk shares drop 7% after growth plan signals tougher competition ahead

Novo Nordisk shares drop 7% after growth plan signals tougher competition ahead

Novo Nordisk's stock fell 7% following its capital markets day where it outlined a growth plan that aligns with industry peers rather than exceeding them, signaling slower future growth. The company highlighted the upcoming loss of U.S. patent exclus...

Market News
Bearish
1 day ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App